Experienced in Arthritis

Irene Lemelle

Vandoeuvre-les-nancy, FR 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Arthritis
Vandoeuvre-les-nancy, FR 
OverviewLocationsClinical Research

Overview

Irene Lemelle practices in Vandoeuvre-les-nancy, France. Ms. Lemelle is rated as an Experienced expert by MediFind in the treatment of Arthritis. Her top areas of expertise are Familial Cold Autoinflammatory Syndrome, Neonatal Onset Multisystem Inflammatory Disease, Muckle-Wells Syndrome, and Juvenile Idiopathic Arthritis (JIA).

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 9 articles and participated in 3 clinical trials in the study of Arthritis.

Gender
Female

Locations

Vandoeuvre-les-nancy, France
Other Locations
Nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients From 1 Year to <18 Years of Age With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Recruiting
Publish Date: December 08, 2025
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
Enrollment Status: Recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JIA)
Enrollment Status: Completed
Publish Date: October 07, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
View 1 Less Clinical Trial

21 Total Publications

Chronic inflammatory arthritis in 22q11.2 deletion (DiGeorge) syndrome: a multicentric study.
Chronic inflammatory arthritis in 22q11.2 deletion (DiGeorge) syndrome: a multicentric study.
Journal: Orphanet journal of rare diseases
Published: June 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Lemelle's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile